Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
18 hedge funds and large institutions have $5.94M invested in Talis Biomedical Corporation Common Stock in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
39% more capital invested
Capital invested by funds: $4.27M → $5.94M (+$1.66M)
5% less funds holding
Funds holding: 19 → 18 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$279K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$65.3K |
| 3 |
BlackRock
New York
|
+$35.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$23.7K |
| 2 |
Morgan Stanley
New York
|
-$9.9K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.46K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$437 |
TLIS Hedge Fund Activity: Q4 2023 in Review
18 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q4 2023, worth a combined $5.94M — up 39% from $4.27M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TLIS and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 7 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $279K. The largest seller was Citigroup, cutting an estimated $23.7K.
- 18 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q4 2023, down from 19 in Q3 2023.
- Funds reported $5.94M of Talis Biomedical Corporation Common Stock stock for Q4 2023, up 39% quarter-over-quarter.
- 2 funds opened new Talis Biomedical Corporation Common Stock positions in Q4 2023 and 3 closed out, a net change of -1 holder.
- The largest Talis Biomedical Corporation Common Stock buyer in Q4 2023 was BML Capital Management, an estimated $279K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q4 2023 was Citigroup, an estimated $23.7K sold.
Based on aggregated 13F filings for Q4 2023.